Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections

AAPS Journal

Volumn 11, Issue 2, 2009, Pages 242-249

  Sonvico, Fabio ^a   Colombo, Gaia ^b   Gallina, Laura ^c   Bortolotti, Fabrizio ^b   Rossi, Alessandra ^a   McInnes, Colin J ^d   Massimo, Gina ^a   Colombo, Paolo ^a   Scagliarini, Alessandra ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MOREDUN RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Cidofovir; Orf virus; Skin infections; Sucralfate; Therapeutic paint; Topical

Indexed keywords

ACICLOVIR; CIDOFOVIR; SODIUM DIHYDROGEN PHOSPHATE; SUCRALFATE;

AEROSOL; ANIMAL CELL; ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RELEASE; DRY DEPOSITION; GEL; HERPES VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LAMB; MONOTHERAPY; MUCOSAL DISEASE; NONHUMAN; PARTICLE SIZE; POXVIRUS INFECTION; SKIN DEFECT; SUSPENSION; VIRUS VIABILITY; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CYTOSINE; DNA, VIRAL; ECTHYMA, CONTAGIOUS; EXCIPIENTS; GELS; ORF VIRUS; PARTICLE SIZE; PHOSPHONIC ACIDS; SHEAR STRENGTH; SHEEP; SKIN; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUCRALFATE;

EID: 68249133860     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9101-8     Document Type: Article

References (22)

1. Zabawski EJ. Jr. A review of topical and intralesional cidofovir. Dermatol Online J. 2000;6:aRticle 3.
2. Stragier I, Snoeck R, De Clercq E, Van Den Oord JJ, Van Ranst M, De Greef H. Local treatment of HPV-induced skin lesions by cidofovir. J Med Virol. 2002;67:241-5.
3. Afouna MI, Fincher TK, Zaghloul AA, Reddy IK. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice. Int J Pharm. 2003;253:159-68.
4. Nettleton PF, Gilray JA, Reid HW, Mercer AA. Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res. 2000;48:205-8.
5. Dal Pozzo F, Andrei G, Holy A, Van Den Oord J, Scagliarini A, De Clercq E, Snoeck R. Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures. Antimicrob Agents Chemother. 2005;49:4843-52.
6. Geerinck K, Lukito G, Snoeck R, De Vos R, De Clerq E, Vanrenterghem Y, Degreef H. A case of human orf in an immunocompromised patient successfully treated with Cidofovir cream. J Med Virol. 2001;64:543-9.
7. Perry BD, Randolph TF, McDermott JJ, Sones KR, Thornton PK. Investing in animal health research to alleviate poverty. Nairobi, Kenya: International Livestock Research Institute; 2002.
8. Lederman ER, Austin C, Trevino I, Reynolds MG, Swanson H, Cherry B, Ragsdale J, Dunn J, Meidl S, Zhao H, Li Y, Pue H, Damon IK. Orf virus infection in children: Clinical characteristic, transmission, diagnostic methods and future therapeutics. Pediatr Infect Dis J. 2007;26:740-4.
9. Gilray JA, Nettleton PF, Pow I, Lewis CJ, Stephens SA, Madeley JD, Reid HW. Restriction endonuclease profiles of orf virus isolates from the British Isles. Vet Rec. 1998;143:237-40.
10. Centers for Desease Control and Prevention (CDC). Orf virus infection in humans-New York, Illinois, California, and Tennessee, 2004-2005. JAMA. 2006;295:992-3.
11. Scagliarini A, McInnes CJ, Gallina L, Dal Pozzo F, Scagliarini L, Snoeck R, Prosperi S, Sales J, Gilray JA, Nettleton PF. Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs. Antiviral Res. 2007;73:169-74.
12. Nagashima R, Yoshida N, Terao N. Selective binding of sucralfate to ulcer lesion. Arzneimittelforschung/Drug Res. 1980;30:80-3.
13. Tumino G. On the cicatrization of venous ulcers and of other nature using sucralfate gel for local application. Acta Pharm Technol. 1994;XV:57-67.
14. Banati A, Chowdhury SR, Mazumder S. Topical use of sucralfate cream in second and third degree burns. Burns. 2001;27:465-9.
15. Conte U, Colombo P, Zagnoli G, Caramella C. Use of sucralfate humid gel as vehicle for drugs having topic activity and for cosmetics. US Patent. 1993;5:246-697.
16. Rossi S, Bonferoni MC, Caramella C, Colombo P, Conte U. Rheological study of sucralfate humid gel: A contribution to the comprehension of its stability properties. Eur J Pharm Biopharm. 1992;32:78-81.
17. Vaira D, Corbelli C, Brunetti G, Menegatti M, Levorato M, Mulè P, Colombo P, Miglioli M, Barbara L. Gastric retention of sucralfate gel and suspension in upper gastrointestinal diseases. Aliment Pharmacol Ther. 1993;7:531-5.
18. Nettleton PF, Brebner J, Pow I, Gilray JA, Bell GD, Reid HW. Tissue culture-propagated orf virus vaccine protects lambs from orf virus challenge. Vet Rec. 1996;138:184-6.
19. Gallina L, Dal Pozzo F, McInnes CJ, Cardeti G, Guercio A, Battilani M, Culli S, Scagliarini A. A realtime PCR assay for the detection and quantification of orf virus. J Virol Met. 2006;134:140-5.
20. Caillé G, Vézina M. Sucralfate drug interaction studies. In: Holande D, Tytgat GNJ editors. SuFralfate: from basic science to the bedside. New York: Springer: 1995. pp. 225-38.
21. Dal Pozzo F, Andrei G, Holy A, Van Den Oord J, Scagliarini A, De Clerq E, Snoeck R. Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures. Antimicrob Agents Chemother. 2005;49:4843-52.
22. Izzedine H. Am J Kidney Dis. 2005;45:804-17.